Q2 FY2026 EarningsQ2 FY26 results missed consensus estimates across all major bottom-line metrics: GAAP EPS was -$1.19 vs. -$0.97 expected, and net loss reached $56.6M vs. the anticipated $46.2M. The variance was driven by higher-than-expected R&D intensity as the company initiated Phase 3 FOS trials. Despite the earnings miss, the cash position of $436.1M remains robust, providing a runway into 2H 2029.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Rapport Therapeutics(RAPP) the EBIT is -60.81 M (-106.2%), Miss estimate;the EPS is -1.19 (-58.67%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
Revenue
TBA--
0.00B--
----
EBITMiss expectations
-0.06B106.15%
-0.05B64.58%
-0.01B41.57%
EPSMiss expectations
-1.1958.67%
-0.96728.93%
-0.223029.74%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf